JP2005068010A5 - - Google Patents

Download PDF

Info

Publication number
JP2005068010A5
JP2005068010A5 JP2003063378A JP2003063378A JP2005068010A5 JP 2005068010 A5 JP2005068010 A5 JP 2005068010A5 JP 2003063378 A JP2003063378 A JP 2003063378A JP 2003063378 A JP2003063378 A JP 2003063378A JP 2005068010 A5 JP2005068010 A5 JP 2005068010A5
Authority
JP
Japan
Prior art keywords
risedronate
pharmaceutical composition
unit dose
composition according
mammal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003063378A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005068010A (ja
Filing date
Publication date
Priority claimed from GBGB9717590.5A external-priority patent/GB9717590D0/en
Priority claimed from GBGB9717850.3A external-priority patent/GB9717850D0/en
Application filed filed Critical
Publication of JP2005068010A publication Critical patent/JP2005068010A/ja
Publication of JP2005068010A5 publication Critical patent/JP2005068010A5/ja
Pending legal-status Critical Current

Links

JP2003063378A 1997-07-22 2003-03-10 骨吸収を抑制する方法 Pending JP2005068010A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5335197P 1997-07-22 1997-07-22
US5353597P 1997-07-23 1997-07-23
GBGB9717590.5A GB9717590D0 (en) 1997-08-20 1997-08-20 Oral method for treating or preventing abnormal bone resorption
GBGB9717850.3A GB9717850D0 (en) 1997-08-22 1997-08-22 Oral method for treating or preventing abnormal bone resorption

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP50991499A Division JP3479780B2 (ja) 1997-07-22 1998-07-17 骨吸収を抑制する方法

Publications (2)

Publication Number Publication Date
JP2005068010A JP2005068010A (ja) 2005-03-17
JP2005068010A5 true JP2005068010A5 (cg-RX-API-DMAC7.html) 2005-06-16

Family

ID=27451690

Family Applications (2)

Application Number Title Priority Date Filing Date
JP50991499A Expired - Lifetime JP3479780B2 (ja) 1997-07-22 1998-07-17 骨吸収を抑制する方法
JP2003063378A Pending JP2005068010A (ja) 1997-07-22 2003-03-10 骨吸収を抑制する方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP50991499A Expired - Lifetime JP3479780B2 (ja) 1997-07-22 1998-07-17 骨吸収を抑制する方法

Country Status (31)

Country Link
EP (5) EP0998292B1 (cg-RX-API-DMAC7.html)
JP (2) JP3479780B2 (cg-RX-API-DMAC7.html)
KR (3) KR100391732B1 (cg-RX-API-DMAC7.html)
CN (3) CN1299689C (cg-RX-API-DMAC7.html)
AT (2) ATE357921T1 (cg-RX-API-DMAC7.html)
AU (1) AU8493698A (cg-RX-API-DMAC7.html)
BG (1) BG66282B1 (cg-RX-API-DMAC7.html)
BR (1) BR9810779A (cg-RX-API-DMAC7.html)
CA (1) CA2294595C (cg-RX-API-DMAC7.html)
CY (2) CY1107535T1 (cg-RX-API-DMAC7.html)
DE (6) DE01201911T1 (cg-RX-API-DMAC7.html)
DK (2) DK0998292T3 (cg-RX-API-DMAC7.html)
EA (1) EA004544B2 (cg-RX-API-DMAC7.html)
EE (1) EE05603B1 (cg-RX-API-DMAC7.html)
ES (3) ES2253136T1 (cg-RX-API-DMAC7.html)
HK (4) HK1042230A1 (cg-RX-API-DMAC7.html)
ID (1) ID24096A (cg-RX-API-DMAC7.html)
IL (1) IL133535A0 (cg-RX-API-DMAC7.html)
IS (3) IS5315A (cg-RX-API-DMAC7.html)
LU (2) LU91222I2 (cg-RX-API-DMAC7.html)
NL (2) NL300223I1 (cg-RX-API-DMAC7.html)
NO (1) NO20000323L (cg-RX-API-DMAC7.html)
NZ (1) NZ501807A (cg-RX-API-DMAC7.html)
PL (1) PL195272B1 (cg-RX-API-DMAC7.html)
PT (2) PT998292E (cg-RX-API-DMAC7.html)
SG (2) SG109478A1 (cg-RX-API-DMAC7.html)
SI (1) SI0998292T1 (cg-RX-API-DMAC7.html)
SK (1) SK932000A3 (cg-RX-API-DMAC7.html)
TR (1) TR200000145T2 (cg-RX-API-DMAC7.html)
UY (1) UY25950A1 (cg-RX-API-DMAC7.html)
WO (1) WO1999004773A2 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2356294C (en) 1998-12-25 2007-06-05 Yamanouchi Pharmaceutical Co., Ltd. Pharmaceutical compositions for treating bone lesions in multiple myeloma
IL146520A0 (en) * 1999-05-21 2002-07-25 Novartis Ag Use of bisphosphonic acids for treating angiogenesis
WO2001005403A1 (en) * 1999-07-19 2001-01-25 Toray Industries, Inc. Drugs for periodontal diseases
IL142515A0 (en) * 1999-12-20 2002-03-10 Merck & Co Inc Pharmaceutical kit
AU2580001A (en) 1999-12-20 2001-07-03 Merck & Co., Inc. Blister package for pharmaceutical treatment card
CA2405360A1 (en) * 2000-04-07 2001-10-18 The Board Of Regents Of The University Of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
RU2288722C2 (ru) * 2000-06-20 2006-12-10 Новартис Аг Способ введения бисфосфонатов
EP1296689B3 (en) 2000-06-20 2013-02-13 Novartis AG Method of administering bisphosphonates
US6638920B2 (en) * 2000-07-21 2003-10-28 Merck & Co., Inc. Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
ES2268086T3 (es) * 2001-05-02 2007-03-16 Novartis Ag Metodo de administracion de bisfosfonatos por inhalacion en el tratamiento o prevencion de la resorcion osea y la osteoporosis.
PL371346A1 (en) 2002-05-10 2005-06-13 F.Hoffmann-La Roche Ag Bisphosphonic acid for the treatment and prevention of osteoporosis
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
WO2005027921A1 (en) * 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a bisphosphonate
WO2005072747A1 (ja) * 2004-02-02 2005-08-11 Ono Pharmaceutical Co., Ltd. 骨吸収抑制剤
BRPI0615770A2 (pt) * 2005-09-16 2011-05-24 Selamine Ltd formulação de bisfosfonato
PT2648702T (pt) * 2010-12-06 2019-03-29 Effrx Pharmaceuticals Sa Formulações de bifosfonatos efervescentes estáveis com caracteristicas de rápida solubilização
CN106924257B (zh) * 2017-03-14 2019-11-19 湖南赛隆药业有限公司 质子泵抑制剂和抗骨质疏松药的复合物及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84731A0 (en) * 1986-12-19 1988-05-31 Norwich Eaton Pharma Heterocycle-substituted diphosphonic acids and salts and esters and pharmaceutical compositions containing them
SE8704436D0 (sv) * 1987-11-13 1987-11-13 Pm Konsult Handelsbolag Anvendning av antisekretoriska substanser for nya indikationer
EP0521388B1 (de) * 1991-07-01 1995-05-10 Gerhard Dr. Gergely Verfahren zur Herstellung einer pharmazeutischen Zubereitung mit wenigstens zwei verschiedenen Wirkstoffen und Verwendung einer solchen Zubereitung
ES2149781T3 (es) * 1991-11-22 2000-11-16 Procter & Gamble Pharma Composiciones de risedronato de liberacion retardada.
US5270365A (en) * 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
US5294433A (en) * 1992-04-15 1994-03-15 The Procter & Gamble Company Use of H-2 antagonists for treatment of gingivitis
WO1994000129A1 (en) * 1992-06-30 1994-01-06 Procter & Gamble Pharmaceuticals, Inc. Use of phosphonates for the treatment of osteoporosis
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
CA2221416A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. Bisphosphonate therapy for bone loss associated with rheumatoid arthritis
CA2254060C (en) * 1996-05-17 2007-05-01 Merck & Co., Inc. Effervescent bisphosphonate formulation

Similar Documents

Publication Publication Date Title
JP2005068010A5 (cg-RX-API-DMAC7.html)
JP2006504795A5 (cg-RX-API-DMAC7.html)
ES2247123T3 (es) Metodo para administrar bisfosfonatos.
HRP20130057T1 (hr) Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom
HRP20230272T1 (hr) Postupci za liječenje cistične fibroze
JP2013121983A5 (cg-RX-API-DMAC7.html)
HRP20161444T1 (hr) Farmaceutski pripravci koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo
ATE350040T1 (de) Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin
JP2002509888A5 (cg-RX-API-DMAC7.html)
IL205262A (en) Use of Risderdone Acid or its Pharmaceutical Salt to produce oral medication once a month for the prevention and treatment of osteoporosis
EA200700049A1 (ru) Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением
JP2013231087A5 (cg-RX-API-DMAC7.html)
DE69940557D1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
WO2006029036A3 (en) Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis
HRP20100276T1 (hr) Gaboksadol za liječenje depresije i drugih afektivnih poremećaja
ATE543491T1 (de) Kombinationspräparat enthaltend ibuprofen und paracetamol
RU2007103306A (ru) Композиции на основе ризедроната и способы их применения
JP2005519936A5 (cg-RX-API-DMAC7.html)
RU2005105691A (ru) Пероральное введение кальцитонина
MXPA04004907A (es) Composiciones de acetaminofen.
JP2002540148A5 (cg-RX-API-DMAC7.html)
RU2006131553A (ru) Комбинация(а) ингибитора топоизомеразы днк и (б) ингибитора iap
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
JP2003503453A5 (ja) ガバペンチンおよびプレガバリンを含む相乗作用組成物